Clinical trial · Interventional
Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma
Prospective, Open-label, Multicenter Clinical Study for the Efficacy and Safety of Recombinant Human Erythropoietin in the Treatment of Anemia in Patients With Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The incidence of lymphoma and anemia is high and the clinical harm is great.However, it has not yet attracted enough clinical attention, and domestic rHuEPO (trade name: Ebio).Shenyang Sansheng Pharmaceutical Co., Ltd.) for lymphoma and anemia patients are less clinical studies.Therefore, a prospective, open-label, multicenter clinical study of recombinant human erythropoietin in the treatment of anemia in patients with lymphoma is planned to analyze the efficacy and safety of recombinant human erythropoietin in patients with lymphoma and anemia, so as to determine the clinical benefits of recombinant human erythropoietin in patients with lymphoma and anemia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| recombinant human erythropoietin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Hemoglobin response rate of subjects during treatment.
- timeFrame
- up to 20weeks
- description
- A hemoglobin response was defined as an increase in hemoglobin levels of ≥ 1.0 g/dL from baseline during 2 or more consecutive assessments (2 weeks apart) without red blood cell infusion.
Secondary outcomes (1)
- measure
- The time of the first hemoglobin response
- timeFrame
- up to 20weeks
- description
- The time of the first hemoglobin response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histopathological diagnosis: lymphoma; 2. Age 14 to 65, no gender limitation; 3. ECOG physical condition score was 0\~3; 4. Life expectancy \>6 months; 5. did not receive recombinant human erythropoietin treatment within 30 days before the first day; 6. Complete liver and kidney function (creatinine ≦1.5\*ULN, BUN≦1.5\*ULN, ALT≦2\*ULN, AST≦2\*ULN, total bilirubin ≦1.5\*ULN;ULN: upper limit of normal value); 7. Willing to sign the informed consent, can understand and abide by the requirements of the study. Exclusion Criteria: 1. Active infections requiring intravenous antibiotic treatment and any active malignancies (except lymphomas); 2. Grade III or IV heart failure, uncontrolled hypertension or hypotension, and associated risk or event of thromboembolism; 3. Severe hepatic and renal insufficiency; 4. Patients who have received radiotherapy or chemotherapy for other tumors (except lymphoma) within 6 months; 5. other anemia diseases (such as aplastic anemia, thalassemia, myelodysplastic syndrome, etc.); 6. Inability to understand and follow the study protocol or inability to sign the informed consent.
References
Publications (0)
Data not yet available